Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. The key shift in the BioXcel Therapeutics story right now ...

Within the last quarter, BioXcel Therapeutics (NASDAQ:BTAI) has observed the following analyst ratings: In the last 3 months, 6 analysts have offered 12-month price targets for BioXcel Therapeutics.

The monster sell-off occurred last Thursday, after BioXcel released the results from a phase 3 clinical trial of its BXCL501, a therapy that targets the agitation suffered by Alzheimer's disease ...

BioXcel Therapeutics latest price target update keeps fair value steady at $16.75 per share, even as a slightly higher discount rate and largely unchanged ~455.2% revenue growth outlook underscore a ...

Aug 14 (Reuters) - BioXcel Therapeutics Inc (BTAI.O), opens new tab said on Monday it will cut more than half of its workforce, as the drugmaker shifts its focus towards developing its agitation ...

BioXcel Therapeutics Inc (NASDAQ:BTAI) shares are trading higher. The AI biopharmaceutical company on Monday announced positive meeting comments from the U.S. Food and Drug Administration (FDA). What ...

Aug 27 (Reuters) - BioXcel Therapeutics (BTAI.O), opens new tab said on Wednesday it plans to seek expanded approval early next year for use of its agitation drug at home after it succeeded in a ...

BioXcel Therapeutics, Inc. (BTAI) on Wednesday said that its late-stage trial evaluating the safety of the company’s BXCL501 as a treatment for agitation associated with bipolar disorders or ...

Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades.

That upgrade hit the headlines early Thursday morning after which investors enthusiastically piled into BioXcel. The upgrader was Goldman Sachs' (NYSE: GS) Corinne Jenkins, who now feels the stock is ...